Skip to main content
Erschienen in: Diabetologia 7/2010

01.07.2010 | Commentary

Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes

verfasst von: J. J. Nolan

Erschienen in: Diabetologia | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Excerpt

Despite advances in understanding of the pathophysiology of type 2 diabetes and the abundance of expert reviews on its treatment, a large gap remains between what is generally believed and what is actually known about treatments for diabetes and their long-term effects. Over a relatively short recent interval the ADA and the EASD have jointly published successive consensus algorithms for the management of hyperglycaemia in patients with type 2 diabetes [1, 2]. The authors of both the 2006 and 2009 consensus algorithms acknowledged in their introductions that while numerous reviews on the treatment of type 2 diabetes have been published in recent years, ‘practitioners are often left without a clear pathway of therapy to follow’ [1, 2]. The most recent algorithm, with its two-tiered approach to metabolic management, has clearly not solved this problem and has itself provoked further debate and commentary [3, 4], including most recently the critique by Schernthaner and colleagues [5] published in the current issue of Diabetologia. …
Literatur
1.
Zurück zum Zitat Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49:1711–1721CrossRefPubMed Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49:1711–1721CrossRefPubMed
2.
Zurück zum Zitat Nathan DM, Buse JB, Davidson MB et al (2009) Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17–30CrossRefPubMed Nathan DM, Buse JB, Davidson MB et al (2009) Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17–30CrossRefPubMed
3.
Zurück zum Zitat De Fronzo RA (2009) From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773–795CrossRef De Fronzo RA (2009) From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773–795CrossRef
4.
Zurück zum Zitat Woo V (2009) Important differences: Canadian Diabetes Association (2008) clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:552–553CrossRefPubMed Woo V (2009) Important differences: Canadian Diabetes Association (2008) clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:552–553CrossRefPubMed
5.
Zurück zum Zitat Schernthaner G, Barnett AH, Betteridge DJ, et al. (2010) Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia. doi:10.1007/s00125-010-1702-3 Schernthaner G, Barnett AH, Betteridge DJ, et al. (2010) Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia. doi:10.​1007/​s00125-010-1702-3
6.
Zurück zum Zitat Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471CrossRefPubMed Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471CrossRefPubMed
7.
Zurück zum Zitat Timmers L, Henriques JP, de Kleijn DP et al (2009) Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53:501–510CrossRefPubMed Timmers L, Henriques JP, de Kleijn DP et al (2009) Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53:501–510CrossRefPubMed
8.
Zurück zum Zitat Noyan-Ashraf MH, Momen MA, Ban K et al (2009) The GLP1 R agonist liraglutide activates cytoprotective pathways and improves outcomes following experimental myocardial infarction in mice. Diabetes 58:975–983CrossRefPubMed Noyan-Ashraf MH, Momen MA, Ban K et al (2009) The GLP1 R agonist liraglutide activates cytoprotective pathways and improves outcomes following experimental myocardial infarction in mice. Diabetes 58:975–983CrossRefPubMed
9.
Zurück zum Zitat Inzucchi SE, McGuire DK (2008) New drugs for the treatment of diabetes: part II—incretin-based therapy and beyond. Circulation 117:574–584CrossRefPubMed Inzucchi SE, McGuire DK (2008) New drugs for the treatment of diabetes: part II—incretin-based therapy and beyond. Circulation 117:574–584CrossRefPubMed
10.
Zurück zum Zitat Kahn SE, Haffner DM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443CrossRefPubMed Kahn SE, Haffner DM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443CrossRefPubMed
11.
Zurück zum Zitat Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777CrossRefPubMed Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777CrossRefPubMed
12.
Zurück zum Zitat Currie CJ, Peters JR, Tynan A et al (2010) Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481–489CrossRefPubMed Currie CJ, Peters JR, Tynan A et al (2010) Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481–489CrossRefPubMed
Metadaten
Titel
Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes
verfasst von
J. J. Nolan
Publikationsdatum
01.07.2010
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 7/2010
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1767-z

Weitere Artikel der Ausgabe 7/2010

Diabetologia 7/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.